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Atg16L1 mediates the cellular degradative process
of autophagy and is considered a critical regulator
of inflammation based on its genetic association
with inflammatory bowel disease. Here we find that
Atg16L1 deficiency leads to an exacerbated graft-
versus-host disease (GVHD) in a mouse model of
allogeneic hematopoietic stem cell transplantation
(allo-HSCT). Atg16L1-deficient allo-HSCT recipients
with GVHD displayed increased T cell proliferation
due to increased dendritic cell (DC) numbers and
costimulatory molecule expression. Reduced auto-
phagy within DCs was associated with lysosomal
abnormalities and decreased amounts of A20, a
negative regulator of DC activation. These results
broaden the function of Atg16L1 and the autophagy
pathway to include a role in limiting a DC-mediated
response during inflammatory disease, such as
GVHD.
INTRODUCTION
Autophagy (also referred to as macroautophagy) consists of
the sequestration of cellular material including organelles and
long-lived proteins within double-membrane vesicles termed au-
tophagosomes and subsequent targeting of this cargo to the
lysosome for degradation and recycling (Yang and Klionsky,
2010). Although initially characterized as a method to maintainviability during periods of nutrient deprivation, a variety of im-
mune functions have been attributed to this pathway including
the degradation of intracellular pathogens, cytokine secretion,
lymphocyte homeostasis, and antigen presentation (Deretic,
2012; Levine et al., 2011; Ma et al., 2013). Consistent with this
critical role in immunity, a common polymorphism in ATG16L1
is associated with a higher incidence of Crohn’s disease, a major
type of inflammatory bowel disease (IBD) (Rioux et al., 2007).
Atg16L1 promotes the conjugation of the ubiquitin-like molecule
LC3 to phosphatidyl-ethanolamine (PE), a step that is required
for the proper formation of the autophagosome (Fujita et al.,
2008). Although complete deletion of the gene is lethal (Saitoh
et al., 2008), we previously generated viable mice that have
reduced Atg16l1 expression and autophagy in all tissues exam-
ined due to insertion of a gene-trap cassette in the Atg16l1 locus
(Cadwell et al., 2009). These Atg16L1 hypomorph (Atg16L1HM)
mice do not display obvious abnormalities in the absence of an
infectious trigger, but they develop intestinal abnormalities
upon norovirus infection (Cadwell et al., 2010). Additionally, we
have found that Atg16L1HM mice display significantly increased
resistance toward intestinal infection by Citrobacter rodentium
that is mediated by an enhanced mucosal immune response
(Marchiando et al., 2013). These findings suggest that Atg16L1
has a broad physiological role in regulating the nature and inten-
sity of the immune response to various inflammatory insults.
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) can be a life-saving procedure for individuals with malig-
nancies, aswell as nonmalignant diseases such as genetic blood
disorders and bone-marrow failure (Jenq and van den Brink,
2010). Allo-HSCT involves the transfer of HSCs from the bone
marrow, peripheral blood, or umbilical cord blood of a donor
into the patient following a conditioning regimen, frequentlyImmunity 41, 579–591, October 16, 2014 ª2014 Elsevier Inc. 579
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this procedure occurs when alloreactive T cells derived from
the donor attack healthy tissue and cause a multiorgan disease
referred to as graft-versus-host-disease (GVHD). Inflammation
causedby theconditioning regimenand subsequent activation of
antigen-presenting cells such as dendritic cells (DCs) contribute
to donor T cell proliferation andmigration to target organs. GVHD
involving the gastrointestinal tract in particular is a major contrib-
utor to transplant-related morbidity and mortality. Intestinal
GVHD shares certain similarities with IBD including genetic sus-
ceptibility conferred by mutations in NOD2, a Crohn’s disease
gene that encodes a bacterial sensor (Henault et al., 2012; Holler
et al., 2004; Landfried et al., 2010; Tanabe et al., 2011). We
previously demonstrated that Nod2/ mice have increased
susceptibility to GVHD in a mouse model of allo-HSCT, further
supporting the resemblance in pathophysiology of IBD and
GVHD (Penack et al., 2009). Despite the emerging understanding
of the immune functions of Atg16L1, and interest in pharmaco-
logically targeting autophagy, the role of this protein in intestinal
GVHD and allo-HSCT outcome has not been examined.
In this study, we define a critical role for Atg16L1 in reducing
morbidity and mortality following allo-HSCT. Atg16L1HM allo-
HSCT-recipientmice developworseGVHDwith increased donor
T cell proliferation and migration to the intestine. We further
demonstrate that autophagy has a cell-intrinsic anti-inflamma-
tory role in DCs that is critical for reducing T cell alloreactivity.
The DC hyperactivity due to Atg16L1 deficiency was associated
with accumulation of aberrant lysosomes and an increase in
Laptm5, a proinflammatory lysosomal protein that enhances
NF-kB signaling by inhibiting the ubiquitin-editing enzyme
A20. These results establish a pivotal role for the autophagy
pathway in limiting DC-mediated T cell alloreactivity in a sys-
temic disease.
RESULTS
Atg16L1 Deficiency IncreasesMorbidity andMortality in
a Mouse Model of Allo-HSCT
To investigate the role of Atg16L1 in allo-HSCT recipients, we
utilized a major histocompatibility complex (MHC) disparate
transplantation model in which T cell-depleted (TCD) bone-
marrow (BM) cells with or without T cells from B10.BR donor
mice were transplanted into lethally irradiated C57BL/6 wild-
type (WT) or Atg16L1HM recipient mice. Because Atg16L1HM
mice are sensitive to the presence of infectious agents including
common mouse pathogens, we initially examined WT and
Atg16L1HM mice that are maintained in an animal facility free of
murine norovirus (MNV), Helicobacter, and segmented filamen-
tous bacteria (SFB). Compared to WT recipients, Atg16L1HM
mice receiving TCD-BM and 23 106 T cells displayed increased
lethality, weight loss, and clinical GVHD score (Figures 1A–1C).
This exacerbated GVHD is T cell-dependent since neither WT
nor Atg16L1HM mice receiving TCD-BM without T cells showed
signs of disease (Figures 1A–1C). Also, the severity of GVHD
was T cell dose-dependent. Transplantation of a lower number
of T cells decreased weight loss and mortality, but GVHD was
still significantly worse in Atg16L1HM compared to WT recipients
(see Figures S1A and S1B available online). The lack of certain
pathogens and commensals commonly found in mouse facilities580 Immunity 41, 579–591, October 16, 2014 ª2014 Elsevier Inc.might explain the absence of lethality in WT recipients in these
experiments. Indeed, we found that an increased number of
WT mice succumbed to lethality when the experiment was
repeated in a second animal facility. However, Atg16L1HM
mice still displayed significantly diminished survival compared
to their WT counterparts, indicating that the role of Atg16L1 in
protection from GVHD is reproducible (Figure S1C). To investi-
gate the role of Atg16L1 in donors, we utilized another common
allo-HSCT model in which irradiated BALB/c mice receive the
transplant from C57BL/6 donors. Again, we found an increase
in morbidity and mortality in BALB/c recipients that received
TCD-BM from Atg16L1HM mice compared to recipients of
TCD-BM from WT mice, in a manner dependent on T cells (Fig-
ures 1D–1F). Thus, Atg16L1 deficiency in either the donor or
recipient leads to worse outcomes after an allo-HSCT.
We took advantage of the consistently early onset of disease in
Atg16L1HM recipient mice in the B10.BR/C57BL/6 model to
further characterize the role of Atg16L1 during allo-HSCT. The
pathophysiology of GVHD involves a feedforward amplification
of the inflammation from the transplant procedure driven by in-
flammatory cytokines and tissue damage (Ferrara and Reddy,
2006). Upon screening a panel of cytokines and chemokines,
we found that Atg16L1HM mice receiving TCD-BM and T cells
had increased amounts of tumor necrosis factor (TNF-a), inter-
leukin-12 (IL-12) p70, macrophage inflammatory protein a
(MIP1a), and IL-7, and a decreased amount of IL-5 compared
to similarly treated WT mice on day 7 posttransplantation (Fig-
ures S1D and S1E). Consistent with a critical role for cytokines
in amplifying the inflammation, administration of anti-TNF-a
antibodies prevented mortality in Atg16L1HM recipient mice
(Figure S1F).
Allo-HSCT was also associated with inflammation of various
target organs including the small intestine, colon, liver, and
skin in both WT and Atg16L1HM recipient mice (Figures S2A–
S2J). Although Atg16L1-deficiency did not lead to increases in
scoring when analyzed by classical semiquantitative histopa-
thology parameters, this lack of obvious differences between
genotypes could be a reflection of the rapid progression from
disease onset to lethality. Therefore, as amore quantitative mea-
sure of intestinal damage, we examined intestinal permeability
because compromised barrier function is one of themost serious
complications associated with GVHD (Takatsuka et al., 2003).
On day 7 after allo-HSCT transplanted with T cells, Atg16L1HM
recipients of BM + T cells displayed significantly more intestinal
permeability compared to WT recipients as determined by the
presence of FITC-dextran in the serum following oral gavage
(Figure 1G). This increase in permeability was not observed in
mice receiving TCD-BM only or mice that were irradiated without
transplantation (Figures 1G and S1G). As predicted by the loss of
barrier function, Atg16L1HM mice receiving TCD-BM and T cells
also had 10-fold higher numbers of bacteria in the spleen and
blood on day 7 (Figures 1H and 1I). Therefore, Atg16L1 is critical
for maintaining intestinal integrity during GVHD in allo-HSCT
recipients.
On the basis of our observations in the mouse model, we
examined the effect of the common T300A polymorphism in
ATG16L1 associated with Crohn’s disease on allo-HSCT
outcome in humans. We analyzed a cohort of 122 patients
receiving an allograft from an HLA-identical sibling (Table S1).
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Figure 1. Atg16L1 Deficiency in Donors and Recipients Increases Morbidity and Mortality in a Mouse Model of Allo-HSCT
(A–C) Lethally irradiated C57BL/6 WT and Atg16L1HM recipient mice were transplanted with 5 3 106 TCD-BM cells with or without 2 3 106 splenic T cells from
donor B10.BR mice and monitored for (A) survival, (B) weight loss, and (C) macroscopic signs of GVHD (see Experimental Procedures). n = 20 recipient mice per
group.
(D–F) Lethally irradiated BALB/c recipient mice were transplanted with 53 106 TCD-BM cells from either C57BL/6WT or Atg16L1HMmice with or without 13 106
T cells from donor WT mice and monitored for (D) survival, (E) weight loss, and (F) macroscopic signs of GVHD. n = 20 recipient mice per group.
(G) Serum FITC-dextran concentration following oral gavage was measured in WT and Atg16L1HM mice on day 7 after irradiation followed by transfer with
TCD-BM with or without T cells from B10.BR mice. n = 5–8 recipient mice per group.
(H and I) Colony-forming units (CFU) of bacteria present in (H) blood and (I) spleen harvested on day 7 fromWT andAtg16L1HMmice receiving TCD-BMwith T cells
from B10.BR mice. N.D. not detected. n = 8 recipient mice per group. Data represent at least two independent experiments. Mean ± SEM are shown in (B), (C),
(E)–(I). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Atg16L1 Prevents Dendritic Cell HyperactivityIndividuals that succumbed to death following tumor relapse
were censored. The presence of ATG16L1T300A in either the
donor or recipient was associated with increased nonrelapse
mortality (Figure S1H and S1I), although only the presence ofthe polymorphism in donors reached statistical significance in
this small cohort. The distribution of the causes of treatment-
related mortality were similar in all groups and were typical
for the procedure; the most common causes of death wereImmunity 41, 579–591, October 16, 2014 ª2014 Elsevier Inc. 581
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Figure 2. Donor T Cells Display Increased Proliferation and Intestinal Homing in Atg16L1-Deficient Recipients
(A–D) Lethally irradiated WT and Atg16L1HM recipients were transplanted with TCD-BM cells and T cells from B10.BR mice, and live H2-Kk+ donor T cells were
analyzed by flow cytometry on day 7. IELs were harvested from the small intestines and the numbers of (A) CD4+, (B) CD8+, and (C) TCRgd+ T cells were
quantified. (D) Mean fluorescent intensity (MFI) of LPAM-1 cell surface expression on donor CD4+ and CD8+ T cells harvested from the spleen. n = 10 recipient
mice per group.
(E–G) Lethally irradiated WT and Atg16L1HM recipients were transplanted with 107 CFSE-labeled splenic T cells from B10.BR donor mice, and recipient spleens
were harvested 96 hr after transfer for analysis by flow cytometry. (E) Representative histograms of CFSE dilution gated on donor CD4+ and CD8+ T cells and (F)
ratios of proliferating to nonproliferating donor T cells are shown. (G) Quantification of the percentages of donor CD4+ and CD8+ T cells expressing CD25. n = 6
recipient mice per group.
(H) Quantification by flow cytometry of the total number and percentages of CD4+CD25+Foxp3+ Tregs in the spleen from the recipient mice in (A–D). Mean ± SEM
are shown in (A–D) and (F–H), and represent two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
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Atg16L1 Prevents Dendritic Cell HyperactivityGVHD, with or without a secondary infection, and idiopathic
pneumonia syndrome, which is a condition due to allogeneic
T cell activity and frequently associated with GVHD. Although
confirmation in a larger prospective study is needed, these
data support a role for ATG16L1 in clinical allo-HSCT outcome.
Atg16L1 Deficiency in Allo-HSCT Recipients Leads to
Increased T Cell Proliferation and Intestinal Homing
Given that the enhanced GVHD observed in Atg16L1-deficient
mice is T cell-dependent, we examined the fate of T cells after
transplantation. Flow cytometric analysis of intraepithelial lym-
phocytes (IELs) indicated that Atg16L1HM recipients had signifi-
cantly increased numbers of donor-derived CD4+, CD8+, and582 Immunity 41, 579–591, October 16, 2014 ª2014 Elsevier Inc.TCRgd+ T cells in the small intestine on day 7 after allo-HSCT
compared to WT recipients (Figures 2A–2C). Consistent with
the increased number of IELs, donor T cells harvested from the
spleen of Atg16L1HM allo-HSCT recipient mice displayed
increased expression of LPAM-1 (a4b7 integrin), a cell adhesion
molecule responsible for T cell homing to the intestine during
GVHD (Petrovic et al., 2004) (Figure 2D). Next, we measured al-
loreactive T cell proliferation by adoptive transfer of donor T cells
labeled with the intravital fluorescent dye carboxyfluorescein
succinimidyl ester (CFSE). A larger fraction of splenic donor
CD4+ and CD8+ T cells displayed CFSE dilution and expressed
CD25 (as a measure of activation) when recovered from the
spleen after transfer into Atg16L1HM recipients compared to
Immunity
Atg16L1 Prevents Dendritic Cell HyperactivityWT recipients, indicating that alloreactive T cells undergo
increased proliferation and activation in Atg16L1-deficient allo-
HSCT recipients (Figures 2E–2G). We also observed a decrease
in the number and relative proportion of FoxP3+ regulatory T cells
in Atg16L1HM recipients compared to WT recipients (Figure 2H).
These results indicate that Atg16L1-deficiency in allo-HSCT
recipients leads to increased donor T cell alloactivation.
Atg16L1-Deficient DCs Have a Higher Activation Status
after allo-HSCT
Our finding that Atg16L1 deficiency in either allo-HSCT donors or
recipients confers susceptibility to exacerbated GVHD suggests
that this protein is functioning within the hematopoietic compart-
ment to increase T cell alloreactivity. CD11c+ antigen presenting
cells, hereon referred to collectively as DCs, are considered to
have a central role in promoting T cell alloreactivity after allo-
HSCT (Hashimoto and Merad, 2011). Quantification of DCs re-
vealed the presence of a higher number of recipient-derived
DCs in the spleen of Atg16L1HM compared to WT recipients on
day 7 after allo-HSCT (Figure 3A). At this time point, there were
very few donor-derived DCs in the spleen, and their numbers
were similar between genotypes. The increase in number of
recipient-derived DCs observed in Atg16L1HM mice was not
due to an expansion of a particular DC subset, and untreated
‘‘pretransplant’’ WT and Atg16L1HM had a similar number of
splenic DCs (Figure 3A). To further examine these DCs, we per-
formed an mRNA microarray analysis on CD11c+ cells from the
spleens of WT and Atg16L1HM allo-HSCT recipients (Table S2).
Consistent with the serum cytokine concentrations, gene set
enrichment analysis (GSEA) indicated that DCs from Atg16L1HM
mice preferentially expressed gene sets associated with TNF-a,
IL-12, and IL-10 signaling (Figures 3B; Table S2). A parallel TNF-
a and IL-10 signature has been observed in human allo-HSCT re-
cipients as well (E.H., unpublished data). This analysis also re-
vealed a transcriptional signature associated with DC matura-
tion, costimulatory signaling, and lysosome function.
Significance of microarray (SAM) analysis identified specific
transcriptional differences (Z score > 2) including decreased
expression of autophagy genesAtg16l1 andAtg7, and increased
expression of costimulatory molecules CD86 and CD80 in
Atg16L1HM samples (Figure S3A). Pathway analysis of the genes
that displayed increased expression in DCs from Atg16L1HM re-
cipients yielded similar results as the GSEA results and indicated
a significant enrichment in gene ontology (GO) terms such as
programmed cell death, cytokine mediating signaling pathway,
cellular response to stress, myeloid leukocyte differentiation,
and others (Figure S3B). Thus, DCs harvested from Atg16L1-
deficient allo-HSCT recipient mice have a hyperactive immune
gene-expression pattern.
To determine whether these transcriptional abnormalities pre-
ceded GVHD, we performed similar microarray analysis on un-
treated pretransplant splenic CD11c+ cells harvested from WT
and Atg16L1HM mice. GSEA and GO term analysis of enriched
transcripts indicated that the above pathways were increased
in DCs from untreated Atg16L1HM mice (Figure 3C; Figures
S3C and S3D; Table S2). Under these conditions, transcriptional
alterations associated with the lysosomewere particularly prom-
inent and included increased expression of autophagy related
genes such as LC3 family members, lysosomal membraneprotein-2 (LAMP-2), and LAMP-1, presumably representing a
compensatory response (Figure S3D). These results reveal a
potential abnormality in lysosomes in Atg16L1-deficient DCs,
which is accompanied by enhanced immune activation that
becomes more prominent following allo-HSCT.
To validate the microarray data, we examined cell surface
expression of costimulatory molecules on splenic DCs by
flow cytometry following allo-HSCT. Host-derived DCs from
Atg16L1HM allo-HSCT recipients displayed increased expres-
sion of the classic costimulatory molecules CD40, CD80,
and CD86 compared to DCs from WT recipients (Figures 3D
and 3E). The relative increase in costimulatory molecule expres-
sion was particularly striking in splenic CD8+CD11c+ and
CD11b+CD11c+ DC subsets (Figures 3F and 3G). However, DC
subsets from the small intestinal lamina propria or mesenteric
lymph nodes (MLNs) of WT and Atg16L1HM mice displayed
similar costimulatory molecule expression (Figures S4A–S4F).
A mixed lymphocyte reaction (MLR) assay has been extensively
used to investigate GVHD because T cell alloreactivity in this
in vitro coculture system mirrors the extent and mechanism
observed in vivo. Thus, we performed a MLR assay with
B10.BR T cells and CD11c+ cells isolated from the spleen by
bead purification on day 7 after allo-HSCT. DCs harvested
from Atg16L1HM allo-HSCT recipients induced greater prolifera-
tion of allogeneic T cells compared to DCs harvested from WT
recipients (Figure 3H). Thus, DCs in Atg16L1-deficient allo-
HSCT recipients display increased activation and capacity to
stimulate allogeneic T cell proliferation.
Atg16L1 Functions within DCs to Prevent Hyperactivity
Because irradiation alone can induce upregulation of CD86 (Diab
et al., 2013), we examined the cell surface expression of this
costimulatory molecule in splenic DCs 24 hr after irradiation.
While irradiation induced a marked increased expression of
CD86 in WT DCs, this increase was more pronounced in DCs
from Atg16L1HM (Figure 4A). Spleens harvested from irradiated
Atg16L1HM mice also had higher numbers of DCs compared to
irradiated WT mice (Figure 4B). Remarkably, culturing bead-pu-
rified splenic CD11c+ DCs from naive Atg16L1HM mice was
sufficient to enhance CD80 and CD86 expression (Figures 4C
and 4D). Thus, although irradiation and transplantation lead to
the largest differences between DCs from WT and Atg16L1HM
mice, these results suggest that Atg16L1-deficient DCs are
more readily activated in general. Therefore, Atg16L1 might
have a role in preventing excess alloreactivity in the absence of
irradiation. To test this possibility, we performed an adoptive
transfer of allogeneic (B10.BR) T cells into either Rag1/ or
Atg16L1HM mice that had been crossed to Rag1/ mice
(HM-Rag1/). Irradiation is not required for transferred T cells
to reconstitute recipients in this model because Rag1/ mice
lack lymphocytes. As predicted, HM-Rag1/ mice displayed
significantly increased weight loss compared to Rag1/ mice
(Figure 4E). Thus, although conditioning with irradiation is a ma-
jor contributor to the increased GVHD in Atg16L1HM recipients,
Atg16L1-deficiency can also exacerbate alloreactivity without
conditioning.
To further test whether Atg16L1-deficient DCs are intrinsically
hyperactive, we performed MLR assays with splenic DCs iso-
lated from untreated mice. Even in the absence of irradiation orImmunity 41, 579–591, October 16, 2014 ª2014 Elsevier Inc. 583
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Figure 3. DC Activation Is Enhanced in Atg16L1-Deficient Allo-HSCT Recipients
(A) Lethally irradiated WT and Atg16L1HM mice received TCD-BM and 23 106 T cells from B10.BR mice as in previous figures, and flow cytometry was used to
quantify CD11c+B220+, CD11c+ CD8+, and CD11b+CD11c+ DC subsets in the spleen on day 7. Similar quantification was performed on splenic DCs from
untreated mice.
(B and C) Microarray analysis was performed on RNA extracted from purified splenic CD11c+ cells from either (B) allo-HSCT recipients on day 7 or (C) untreated
mice as in (A). Enrichment score from GSEA shown. Extended analyses provided in Table S2. n = 34 biological replicates each.
(D) Representative histograms of CD40, CD80, and CD86 cell surface expression on total CD11c+I-AE+ recipient DCs detected by flow cytometry on day 7 after
allo-HSCT.
(E–G) Quantification of CD40, CD80, and CD86 (MFI) from the flow cytometry analysis in (D) gated on (E) total CD11c+, (F) CD8+CD11c+, and (G) CD11b+ CD11c+
cells.
(H) Purified CD11c+ cells fromWT and Atg16L1HM recipient mice were cocultured with B10.BR T cells at a 1:1 ratio for 72 hr, and proliferation was determined by
3H-thymidine incorporation. Bar graphs show mean ± SEM and represent at least 5 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 4. Atg16L1 Functions within DCs to Prevent Hyperactivity
(A) MFI of CD86 expression in CD11b+ splenic DCs analyzed by flow cytometry 24 hr after WT and Atg16L1HM mice were lethally irradiated.
(B) Quantification of indicated DC subsets by flow cytometry in the spleen of WT and Atg16L1HM mice 7 days after sublethal irradiation (550cGy).
(C and D) CD11c+ splenic cells isolated from untreated WT or Atg16L1HM mice were cultured in media containing GM-CSF for 24 hr, and CD80 and CD86
expression was analyzed by flow cytometry. n = 5 per group. (C) Representative histograms and (D) percentages of CD80+ and CD86+ cells are shown.
(E) Rag1/ or Atg16L1HM-Rag1/ mice were injected intravenously with 2 3 106 allogeneic (B10.BR) T cells and monitored for weight loss. n = 8 per group.
(F–H) 3H-thymidine incorporation was measured in allogeneic B10.BR T cells cocultured at a 1:1 ratio for 72 hr with either (F) purified splenic DCs, (G) purified
splenic DCs and 10 mg/ml blocking antibodies against the indicated costimulatory molecules, or (H) BMDCs. Relative proliferation was determined by normalizing
data to the mean WT value.
(I) Lethally irradiated Atg16L1DCD11c recipient mice were transplanted with TCD-BM cells with or without 2 3 106 T cells from donor B10.BR WT mice and were
monitored for survival. n = 8–10 per group. Data in (A), (B), (D), (E), and (F)–(H) represent mean ± SEM. Data are representative of at least two independent
experiments. *p < 0.05, **p < 0.01.
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Atg16L1 Prevents Dendritic Cell Hyperactivitytransplantation, DCs harvested from Atg16L1HM mice induced
increased alloreactive T cell proliferation compared to DCs
from WT mice (Figure 4F). The addition of blocking antibodies
against CD80, CD86, and CD40 inhibited T cell proliferation,
demonstrating that the enhanced DC activity is dependent on
costimulatory molecules (Figure 4G). Moreover, we found that
BM-derived DCs (BMDCs) from Atg16L1HM mice were also
able to induce increased alloreactive T cell proliferation (Fig-
ure 4H). These results indicate that Atg16L1 has a cell-intrinsic
role in DCs that prevents excess alloreactive T cell proliferation
in vitro. Next, we generated mice with a cell-type-specific dele-
tion of Atg16L1 in CD11c+ cells by breeding Atg16l1flox/flox mice
with Cd11c-Cre mice (Atg16L1DCd11c) to examine the role of this
gene in DCs in vivo (Figure S4G). Compared to Atg16l1flox/flox
controls, Atg16l1DCd11c recipients displayed increased lethality
and morbidity following allo-HSCT (Figures 4I and S4H).
Atg16l1DCd11c mice had increased numbers of DCs in the spleen
compared to controls following irradiation, and culturing DCs
from these mice led to increased CD80 expression as well (Fig-
ures S4I and S4J). Although Atg16L1-deficiency in other cell
types is also likely contribute to allo-HSCT outcome, these re-
sults indicate that deletion in DCs is sufficient to confer exacer-
bated GVHD. These experiments collectively indicate that
Atg16L1 function within the DC compartment has a critical role
in preventing excess T cell alloreactivity in vitro and during
GVHD.
Costimulatory Molecule Expression Is Associated with
Autophagy Activity
Granulocyte macrophage colony-stimulating factor (GM-CSF), a
DC growth factor frequently added to culture media including in
our assays, has been shown to induce autophagy (Zhang et al.,
2012). We found that the presence of GM-CSF in the media of
cultured splenic DCs harvested from WT mice led to a large
increase in the number of LC3+ dots detected by immunofluores-
cence (IF), a marker of autophagy (Figures 5A–5C). In contrast,
DCs from Atg16L1HMmice displayed dysmorphic large LC3+ ag-
gregates in resting conditions that were absent in WT cells, and
there was a smaller increase in LC3+ structures upon GM-CSF
treatment (Figures 5A–5C). These results are consistent with
the increase in autophagy-related transcripts observed in DCs
harvested from untreated Atg16L1HM mice (Figure S3D). These
results were also confirmed by immunoblot analysis in which
we detected more LC3 in DCs from Atg16L1HM mice under
resting conditions (Figure 5D). While the addition of GM-CSF to
DCs from WT mice led to an increase in the active form of LC3
(LC3-II) that was stabilized by the lysosomal inhibitor NH4Cl,
only a small amount of LC3-II was detectable in DCs from
Atg16L1HM mice after GM-CSF treatment (Figure 5D). We also
confirmed these results during in vivo irradiation with the auto-
phagy substrate p62 as a marker. Whole-cell lysates of the
spleen from irradiated WT mice displayed significantly reduced
p62 expression compared to untreated controls, whereas sam-
ples fromAtg16L1HMmice retained high amounts of p62 (Figures
5E and 5F). These results are consistent with a partial reduction
in autophagy and failure to fully execute the pathway upon in-
duction (He et al., 2013; Murthy et al., 2014).
Our findings suggest that it might be possible to reduce the
amount of costimulatory molecule expression by inducing586 Immunity 41, 579–591, October 16, 2014 ª2014 Elsevier Inc.autophagy. We tested this possibility by culturing purified
splenic DCs in the presence of a panel of known inducers
of autophagy—rapamycin, lithium, spermadine, and resvera-
trol (Fleming et al., 2011). All of these agents reduced CD80
expression on WT DCs to various extents (Figure 5G). We
next examined whether these autophagy inducers can reduce
CD80 expression in Atg16L1HM DCs, which retain some de-
gree of autophagy function. We found that addition of spermi-
dine and resveratrol, the two agents that had the largest ef-
fect on WT DCs, led to reversal of the enhanced CD80
expression to amounts expressed in WT DCs (Figure 5H).
Together with the above experiments, these results indicate
that autophagy activity is inversely associated with DC
hyperactivity.
Atg16L1 has been shown to prevent excess IL-1b production,
most likely downstream of reactive oxygen species (ROS)
produced by mitochondria that accumulate in the absence of
autophagy (Saitoh et al., 2008). Thus, it is possible that the
hyperactivity observed in Atg16L1-deficient DCs is mediated
by enhanced cytokine or ROS production. However, antibody-
mediated blockade of IL-1b or its receptor did not affect the
increased capacity of Atg16L1HM DCs to stimulate alloreactive
T cell proliferation (Figure S5A). Although an IL-12 signature
was detected in Atg16L1-deficient DCs (Figures 3B and 3C),
blocking this cytokine did not reduce DC hyperactivity either.
Also, transfer of Atg16L1HM culture supernatant onto WT DCs
did not transfer the increase in costimulatory molecule expres-
sion (Figure S5B). Additionally, we did not find differences in
the amount of superoxide and hydroxy radicals when comparing
WT and Atg16L1HM DCs (Figures S5C and S5D). These results
suggest that Atg16L1-deficiency confers DC hyperactivity
through a distinct mechanism.
Atg16L1 Deficiency Results in Lysosomal Abnormalities
and Decreased A20 Expression
On the basis of the role of autophagy in membrane trafficking
and organelles maintenance, we analyzed Atg16L1-deficient
DCs for the presence of ultrastructural abnormalities by
transmission electron microscopy (TEM). Instead of defects in
mitochondria, we observed a striking increase in the number of
electron-dense lysosomal structures in cultured Atg16L1HM
DCs compared to WT controls (Figures 6A-E). The accumulation
of these lysosomal structures were not an artifact of culturing
because we observed similar electron-dense organelles in DCs
isolated from untreated or irradiated mice without culturing (Fig-
ures S6A–S6D). In addition to an overall increase in lysosomes,
we detected the accumulation of dysmorphic organelles that
are morphologically similar to structures referred to as telolyso-
somes (Brunk and Terman, 2002). Accumulation of these vesi-
cles has been associated with defective autophagy and
decreased lysosomal activity (Levine and Kroemer, 2008). We
corroborated these findings by flow cytometry. Atg16L1HM
DCs displayed an increase in total lysosomal load, as well as
pH neutral dysfunctional lysosomes, which were detected by
LysoTracker and LysoSensor Green staining, respectively (Fig-
ures 6F and 6G). Also, we found that disrupting the lysosomal
membrane with sphingosine (Ullio et al., 2012) was sufficient
to increase CD80 expression in WT DCs (Figure 6H). These re-
sults indicate that hyperactivity in Atg16L1-deficient DCs is
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Figure 5. Costimulatory Molecule Expression Is Associated with Autophagy Activity
(A–C) CD11c+ splenic cells isolated fromWT and Atg16L1HMmicewere cultured with or without GM-CSF for 5 hr and stained for LC3 andDAPI. (A) Representative
immunofluorescence images, (B) quantification of LC3+ dots per cell, and (C) fold increase in the number of LC3+ dots in DCs treated with GM-CSF relative to
untreated cells are shown.
(D)Whole-cell lysates fromDCs cultured as in (A) were analyzed by immunoblot for LC3 and actin. Where indicated, cells received NH4Cl during the 5 hr culture to
prevent degradation of LC3-II. Values displayed below represent the ratio of LC3-II over actin. Cells were pooled from 3 mice per genotype.
(E and F) Immunoblot analysis and quantification of p62 relative to actin in the spleen harvested from WT and Atg16L1HM mice on day 7 after lethal irradiation.
(G and H) Flow cytometric analysis of CD80 expression on CD11c+ splenic cells from (G) WT and (H) Atg16L1HM mice cultured in GM-CSF containing media
overnight and the indicated concentrations of rapamycin, spermidine, lithium, or resveratrol. Autophagy inducing agents were added during the last 6–12 hr prior
to analysis. Bar graphs represent mean ± SEM, n = 3 mice per condition. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 6. Atg16L1 Deficiency Results in Lysosomal Abnormalities
(A–H) Splenic DCs isolated from WT and Atg16L1HM mice were cultured in GM-CSF containing media for 24 hr and analyzed by flow cytometry or TEM. (A)
Percentage of cells displaying high MitoTracker incorporation by flow cytometry. (B) Quantification of mitochondria detected per cell by transmission electron
microscopy (TEM). (C) Representative TEM images of splenic DCs (cultured in GM-CSF containing media for 24 hr. i, multivesicular bodies; ii, lysosomes; and iii,
dysmorphic vesicles). (D) Quantification of lysosomes, dysmorphic vesicles, and multivesicular bodies detected per cell by TEM. (E) Quantification of the per-
centage of vesicles detected in (C) that are electron dense. (F) Percentage of cells displaying high LysoTracker incorporation. (G) Representative histogram of
LysoSensor DND-152 incorporation and quantification of the percentage of cells displaying high staining. (H) Flow cytometric analysis of CD80 expression onWT
DCs cultured with or without 25 mM sphingosine for 3 hr. Bar graphs represent mean ± SEM, n = 3–6 mice per condition. Scale bar represents 10 mm for (A) and
2 mm for (F). *p < 0.05, **p < 0.01, ****p < 0.0001.
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some compartment.
These findings are in concert with our microarray data indi-
cating that Atg16L1 deficiency leads to increased lysosomal
transcription. Of particular interest was an increase in Laptm5,
a lysosomal transmembrane protein that promotes the degrada-
tion of several targets involved in immune signaling including the
ubiquitin-editing enzyme A20 (Glowacka et al., 2012; Kawai
et al., 2014; Ouchida et al., 2010; Ouchida et al., 2008). As a
potent inhibitor of NF-kB and mitogen-activated protein kinase
(MAPK) signaling, A20 is a key negative regulator of DC activity
(Ganguly et al., 2013). Mice with DC-specific deletion of A20
display increases in DC numbers and costimulatory molecule
expression, which causes enhanced T cell alloreactivity and sys-
temic autoimmunity (Hammer et al., 2011; Kool et al., 2011).
Therefore, an increase in Laptm5 due to Atg16L1 deficiency is
predicted to downregulate A20, potentially explaining the in-
crease in DC numbers and costimulatory molecule expression
observed in Atg16L1HM mice. We first validated the microarray588 Immunity 41, 579–591, October 16, 2014 ª2014 Elsevier Inc.data by qRT-PCR on independent samples and confirmed that
Laptm5 expression is increased in Atg16L1HM DCs in the same
conditions in which costimulatory molecule expression is
increased (Figure S6E). Next, we found that A20 expression
was decreased in Atg16L1HM DCs (Figures S6F and S6G).
Also, we found that this decrease in A20 was associated with a
corresponding increase in phosphorylated IkB and JNK, indica-
tive of augmented NF-kB and MAPK signaling (Figures S6F and
S6G). Because CD80, CD86, and CD40 expression is regulated
by these signaling pathways (Fong et al., 1996; Hinz et al., 2001;
Zhao et al., 1996), these findings are consistent with the
increased activation observed in Atg16L1HM DCs (Figure S6H).
DISCUSSION
Here we have shown that the autophagy gene Atg16l1 protects
against exacerbated GVHD following allo-HSCT. In addition to
significantly worse morbidity and mortality, Atg16L1HM allo-
HSCT recipients displayed a compromised intestinal barrier
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activation, and migration to the gastrointestinal tract. Atg16L1-
deficiency in transplant donors also exacerbated GVHD in
recipients, suggesting that this protein is functioning in a he-
matopoietic cell type during allo-HSCT. Several lines of evidence
indicate that this increased GVHD and T cell alloreactivity is due
to the effect of Atg16L1-deficiency in DCs. A higher number of
recipient-derived DCs were recovered from Atg16L1HM recipient
mice, and these DCs had a hyperactive gene-expression profile.
DCs from Atg16L1HM recipient mice also displayed elevated
surface expression of costimulatory molecules known to have
a role in acuteGVHD and T cell alloreactivity. Moreover, DCs har-
vested directly from untreated Atg16L1HM mice, as well as DCs
differentiated from Atg16L1HM BM, were able to stimulate
increased donor T cell proliferation in vitro compared to their
WT counterparts. Further, mice with cell-type-specific deletion
of Atg16L1 in DCs displayed worse allo-HSCT outcomes, and
DCs harvested from these mice had increased costimulatory
molecule expression. Our results are most consistent with a
model in which Atg16L1-deficient DCs overstimulate allogeneic
T cells that proliferate and migrate to peripheral organs such as
the intestine to cause damage. The ensuing disruption of the
intestinal barrier most likely plays a critical role in accelerating
disease through a feedforward loop of additional DC and T cell
activation, which ultimately results in lethality.
In contrast to other situations in which autophagy supports
antigen presentation by DCs (Cooney et al., 2010; Jagannath
et al., 2009; Ma et al., 2012; Reed et al., 2013; Romao et al.,
2013), we found a major immunosuppressive function of
Atg16L1 in this cell type. This discrepancy likely reflects the
pathophysiology of GVHD, which does not necessarily rely on
the proper trafficking of one particular antigen and can be
driven by either MHC class I or II molecules. In the context of
our studies, Atg16L1 deficiency might prime the cells for hyper-
activity in response to stress. Irradiation of Atg16L1HM mice or
culturing DCs from these mice in conditioned media was suffi-
cient to enhance costimulatory molecule expression. Also,
Atg16L1-deficient DCs displayed alterations in gene expression
that preceded transplantation, especially in transcripts associ-
ated with lysosomes. This finding is similar to previous studies
that observed a compensatory increase in endolysosomal gene
expression following autophagy inhibition in the intestinal
epithelium (Cadwell et al., 2010; Patel et al., 2013). One of
these genes increased in Atg16L1-deficient DCs was Laptm5,
which has been shown to induce proinflammatory activity in
macrophages by downregulating A20 (Glowacka et al., 2012).
Consistent with other studies demonstrating a key role for
A20 in preventing DC hyperactivity (Hammer et al., 2011; Kool
et al., 2011), we find that increased Laptm5 in Atg16L1-defi-
cient DCs is associated with a decrease in A20 and a corre-
sponding increase in inflammatory signaling. How Laptm5 tar-
gets A20 for degradation is not known. Interestingly, Laptm5
has signaling functions in other immune cell types (Glowacka
et al., 2012; Kawai et al., 2014; Ouchida et al., 2010; Ouchida
et al., 2008), and overexpression is associated with accumula-
tion of immature lysosomal vesicles, defective autophagy, and
cell death in neuroblastomas (Inoue et al., 2009). Therefore, un-
derstanding the relationship between autophagy and this poorly
understood lysosomal protein might be key to deciphering thecomplex relationship between lysosomes and inflammatory
signaling in a variety of cell types.
These observations in a murine model of allo-HSCT might
have important implications for assessing GVHD risk in humans.
The IBD risk allele of ATG16L1 leads to a T300A mutation
that destabilizes the protein product in the presence of TNF-a
and metabolic stress by facilitating caspase-3-mediated cleav-
age (Lassen et al., 2014; Murthy et al., 2014). Our preliminary
analysis of patients lacks the power to determine whether the
ATG16L1T300A allele is a true risk factor for GVHD due to other
factors that can contribute to mortality following allo-HSCT.
However, we were able to observe an association between
this polymorphism and an adverse transplantation outcome
even in a small cohort. Given the high frequency with which the
ATG16L1T300A allele occurs in the human population, further
studies (both retrospective and prospective) seem warranted
to determine whether the presence of this allele in donor and/
or host affects transplant outcome, in particular GVHD. Our
mouse model also indicates that it will be important to examine
the effect of the ATG16L1T300A allele on DCs, which is currently
unclear (Strisciuglio et al., 2013; Wildenberg et al., 2012).
Finally, our findings provide experimental support for the
concept that intestinal GVHD and IBD share underlying mecha-
nisms responsible for the common pathophysiology observed
between patients and animal models of each disease. In this
context, it is notable that HM/Rag1/ mice develop exagger-
ated disease upon transfer of allogeneic T cells in a model that
resembles the T cell transfer colitis model frequently used in
IBD studies. Our findings raise the possibility that therapeutically
targeting DCs, potentially through manipulation of autophagy,
could ameliorate intestinal barrier dysfunction inmultiple disease
settings.
EXPERIMENTAL PROCEDURES
Mice and Bone-Marrow Transplantation
Atg16L1HM and Atg16l1flox/flox mice have been described previously (March-
iando et al., 2013). WT refers to wild-type C57BL/6J mice initially purchased
from Jackson Laboratory and bred onsite to generate animals for experimen-
tation. BALB/c, B10.BR, and Cd11c-Cre mice were purchased from Jackson
Laboratory. Atg16l1DCd11c mice and littermate Atg16l1flox/flox control mice
used in experiments were generated from Atg16l1flox/flox and Atg16l1flox/flox
Cd11c-Cre breeding pairs in which one parent was hemizygous for the Cre
allele. Mice used in this study were 6- to 9-week-old females at the outset
of the experiment. Bone-marrow (BM) transplantations were performed as
previously described (Jagannath et al., 2009; Penack et al., 2010) with 1,100
cGy (C57BL/6) or 850 cGy (BALB/c) split-dosed irradiation of recipients
transplanted with 5 3 106 BM cell after T cell depletion with anti-Thy-1.2
and low-TOX-M rabbit complement (Cedarlane Laboratories). Donor T cells
were prepared by harvesting splenocytes and enriching T cells by Miltenyi
MACS purification of CD5. Recipient mice were monitored daily for survival
and disease was quantified weekly for 5 clinical parameters (weight loss,
hunched posture, activity, fur ruffling, and skin lesions) on a scale from 0 to
2. A clinical GVHD score was generated by the summation of the 5 criteria
as previously described (Cooke et al., 1996). Last observation was carried
forward for weight loss and clinical GVHD score for allo-HSCT experiments.
All animal studies were performed according to approved protocols by the
New York University School of Medicine andMemorial Sloan Kettering Cancer
Center Institutional Animal Care and Use Committees (IACUCs).
Flow Cytometry and Cell Culture
All antibodies were obtained fromBDBiosciences or BioLegend. CD11c+ cells
were isolated from spleen by performing a collagenase and DNase digestionImmunity 41, 579–591, October 16, 2014 ª2014 Elsevier Inc. 589
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Atg16L1 Prevents Dendritic Cell Hyperactivity(Roche) at 37C for 15min followed byMACS sorting with CD11c+microbeads
(Miltenyi). Cells were prepared for flow cytometry as previously described
(Petrovic et al., 2004) and analyzed by LSR II flow cytometer (BD Biosciences)
and FlowJo (TreeStar Software).
qRT-PCR and Microarray Gene-Expression Profiling
MACS purified CD11c+ cells from spleens of allo-HSCT recipients on day 7 or
untreated mice were placed directly into TRIzol LS (Invitrogen). mRNA was
isolated, amplified, and hybridized to an Affymetrix GeneChip (MOE430A).
Affymetrix Power Tools software was used for processing and quantile
normalization of fluorescence hybridization signals by the robust multichip
averaging method (Irizarry et al., 2003). Transcripts were log2-normalized
and average values for technical replicates were obtained for analysis
of change in expression using Significance Analysis of Microarray (SAM).
Differential gene expression was assessed with the Bioconductor package
‘‘siggenes’’ with a fold change cutoff of > 2. Full results, including p values
and multiple-testing corrected q values, are included in Table S2. The Broad
Institute GSEA software was used for GSEA as previously described (Subra-
manian et al., 2005). Primers for Laptm5: Forward-GCGGTAAAGTGTCCTG
TAGGTTC; Reverse- TCTTGACCACGCCGAACAGCAG.
Statistics
GraphPadPrismversion6wasused for statistical analysis.Differencesbetween
means were evaluated by two-tailed unpaired t test or one-way ANOVA and
Holm-Sidak’s for experiments involving multiple comparisons. Survival was
analyzed with the Mantel-Cox log rank test. The means of the area under the
curve was used to compare longitudinal weight loss and disease scores be-
tween conditions.Mann-Whitney test was used for analysis of intestinal perme-
ability and bacterial translocation because data were not normally distributed.
Additional details are provided in the Supplemental Experimental
Procedures.
ACCESSION NUMBERS
The GEO accession numbers for the microarray data reported in this paper are
GSE61560 (splenic DCs day 7 after allo-HSCT) and GSE61559 (splenic DCs
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